UroGen Pharma Presents New Data From A Long-Term Follow-Up Study Published In The Journal Of Urology Online To The OLYMPUS Trial Show Median Duration Of Response Of 4-Years In Patients Who Achieved A Complete Response With JELMYTO

BenzingaNov 26 08:09 ET

New Data From a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response With JELMYTO

UroGen PharmaNov 26 00:00 ET

Further Weakness as UroGen Pharma (NASDAQ:URGN) Drops 13% This Week, Taking Five-year Losses to 64%

Simply Wall StNov 18 06:14 ET

UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript Summary

moomoo AINov 6 17:21 ET · Conference Call

UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript

Earnings Call TranscriptsNov 6 17:12 ET

TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $35

Moomoo NewsNov 6 15:31 ET · Ratings